Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial
Academic Article
Publication Date:
2021
abstract:
Treatment options for severe CRSwNP are limited. Dupilumab is a safe, well-tolerated, and effective alternative in patients with poor control of symptoms, corticosteroid-dependent disease, and high rates of recurrence of nasal polyps after surgery.
Iris type:
1.1 Articolo in rivista
Keywords:
anti–IL-13; anti–IL-4; biologic agents; chronic rhinosinusitis; dupilumab; DUPIXENT; monoclonal antibody; nasal polyposis; type 2 inflammation
List of contributors:
Trimarchi, M.; Indelicato, P.; Vinciguerra, A.; Bussi, M.
Published in: